netFormulary NHS
Demonstration Formulary
 Search
 Results

Looking for Trastuzumab found 18 matches

   


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section NICE TA107: Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer (08.01.05)
link in drug section NICE TA107: Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer (08.01.05)
link in drug section NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab  (08.01.05)
link in drug section NICE TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (08.01.05)
link in drug section NICE TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (08.01.05)
link in drug section NICE TA257: Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (08.01.05)
link in drug section NICE TA257: Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (08.01.05)
link in drug section NICE TA34: Breast cancer - trastuzumab (08.01.05)
link in drug section NICE TA34: Guidance on the use of trastuzumab for the treatment of advanced breast cancer (08.01.05)
link in drug section NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (08.01.05)
link in drug section NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (08.01.05)
link in drug section NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (08.01.05)
link in drug section NICE TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab (08.01.05)
link in drug section NICE TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (08.01.05)
link in drug section NICE TA704: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies (08.01.05)
link in drug section NICE TA786: Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies (08.01.05)
link in drug section TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (08.01.03)
link in drug section TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (08.01.03)


 
netFormulary